July 15, 2026

NOTE: This article was originally published in June 2026 as part of our PharPoint of View LinkedIn newsletter. Each month, our PharPOV series shares perspectives from across the PharPoint team: operational insights, trending topics, and stories about the behind-the-scenes collaboration that keeps studies moving. This article shares the perspective of Melisa Williamson, PharPoint’s Director of Quality Assurance.

How mature is your organization’s quality culture?

Recent (FY2025) FDA inspection observation trends showed that most findings are not driven by a missing procedure or system, but by weaknesses in how quality systems are applied in practice; particularly around decision making, escalation, investigation effectiveness, CAPA execution, and oversight. These recurring observations reinforce that regulators are increasingly assessing how teams think, decide, and act under real‑world conditions, not simply what is written in SOPs; in short, assessing quality culture.

We’ve developed this Quality Culture Maturity Assessment to support a more meaningful conversation about the consistency with which quality principles are understood, applied, and sustained across organizations and partnerships. The intent was to create a practical, structured tool that goes beyond the presence of procedures and instead encourages reflection on how quality is embedded into leadership behaviors, systems, people, and everyday decision making across the clinical trial lifecycle.

This assessment is designed as a self‑reflection tool, not an audit, inspection, or performance evaluation. It provides a common framework organizations can use to understand their current state, identify areas of developing maturity, and prioritize improvements that strengthen proactive, risk‑based approaches to quality.

We encourage you to use this assessment as a starting point; complete it candidly, reflect on the results, and consider how the insights can inform ongoing quality discussions within your organization and across our shared work. Re‑visiting the assessment periodically can help gage progress over time and support continuous improvement.

We appreciate your engagement and your continued commitment to advancing quality across our shared work. This assessment is offered in the spirit of transparency and collaboration, with the goal of supporting aligned expectations, continuous improvement, and confidence in the conduct and oversight of clinical research.

ASSESS YOUR ORGANIZATION’S QUALITY MATURITY

To use this free tool, visit: https://assessingqualitymaturity.org/

About the assessment: This tool is designed for biotechnology and pharmaceutical companies evaluating the maturity of their quality culture, systems, and processes. Results serve as a general guide aligned with ICH E6(R3) and ICH E8 guidelines, and are not a substitute for professional evaluation. The assessment evaluates your organization across 7 quality dimensions (leadership – systems – people – improvement – quality by design – technology – external) with 21 questions total.

Privacy notice: Your responses on the quality assessment are not saved or collected by PharPoint Research. Refreshing or closing your browser will clear all data.

About the Author

Melisa Williamson, Director of Quality Assurance

Melisa Williamson has over 14 years of experience working to improve efficiency and durability of processes within clinical research. Her experience spans multiple GXP environments, including managing and directing GCP Quality Assurance (QA) at various sponsors and CROs.

In her role at PharPoint, Melisa oversees quality initiatives within the organization and provides consultative support for sponsors navigating quality challenges.

Melisa is an experienced speaker within the clinical quality space with topics including Risk Based Quality Management (RBQM) and Quality by Design (QbD). She holds a BS in Biobehavioral Health at Pennsylvania State University.

RELATED RESOURCES